These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35790103)

  • 1. ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.
    Xiao Z; Alam IS; Simonetta F; Chen W; Scheller L; Murty S; Lohmeyer JK; Ramos TL; James ML; Negrin RS; Gambhir SS
    Blood Adv; 2022 Aug; 6(16):4782-4792. PubMed ID: 35790103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease.
    Alam IS; Simonetta F; Scheller L; Mayer AT; Murty S; Vermesh O; Nobashi TW; Lohmeyer JK; Hirai T; Baker J; Lau KH; Negrin R; Gambhir SS
    Cancer Res; 2020 Nov; 80(21):4780-4790. PubMed ID: 32900772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
    Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
    Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.
    Sato M; Storb R; Loretz C; Stone D; Mielcarek M; Sale GE; Rezvani AR; Graves SS
    Transplantation; 2013 Jul; 96(1):34-41. PubMed ID: 23694952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.
    Simonetta F; Alam IS; Lohmeyer JK; Sahaf B; Good Z; Chen W; Xiao Z; Hirai T; Scheller L; Engels P; Vermesh O; Robinson E; Haywood T; Sathirachinda A; Baker J; Malipatlolla MB; Schultz LM; Spiegel JY; Lee JT; Miklos DB; Mackall CL; Gambhir SS; Negrin RS
    Clin Cancer Res; 2021 Feb; 27(4):1058-1068. PubMed ID: 33087332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
    Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
    Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
    Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.
    Hubbard VM; Eng JM; Ramirez-Montagut T; Tjoe KH; Muriglan SJ; Kochman AA; Terwey TH; Willis LM; Schiro R; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
    Blood; 2005 Nov; 106(9):3285-92. PubMed ID: 15956289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease.
    Graves SS; Parker MH; Stone D; Sale GE; Pillai SPS; Johnson MM; Storb R
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):50-54. PubMed ID: 28958896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
    Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
    J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
    Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
    Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.
    Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD.
    Parker MH; Stone D; Abrams K; Johnson M; Granot N; Storb R
    Transplantation; 2021 May; 105(5):1008-1016. PubMed ID: 33065723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model.
    Burlion A; Brunel S; Petit NY; Olive D; Marodon G
    Front Immunol; 2017; 8():756. PubMed ID: 28713380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3-kinase-independent signaling pathways contribute to ICOS-mediated T cell costimulation in acute graft-versus-host disease in mice.
    Li J; Heinrichs J; Leconte J; Haarberg K; Semple K; Liu C; Gigoux M; Kornete M; Piccirillo CA; Suh WK; Yu XZ
    J Immunol; 2013 Jul; 191(1):200-7. PubMed ID: 23729441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
    Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
    Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD.
    Fujimura J; Takeda K; Kaduka Y; Saito M; Akiba H; Yagita H; Yamashiro Y; Shimizu T; Okumura K
    Pediatr Transplant; 2010 Jun; 14(4):540-8. PubMed ID: 20136724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
    Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.